# Low, plasma level‑informed native curcumin concentrations fail to induce cell death in human lung and colorectal cancer cells

**Authors:** Ilma Imtiaz, Janet Schloss, Andrea Bugarcic

PMC · DOI: 10.1080/13880209.2026.2640678 · Pharmaceutical Biology · 2026-03-19

## TL;DR

This study finds that low concentrations of curcumin, similar to those in the blood, do not kill lung and colorectal cancer cells and may even help them survive.

## Contribution

The study evaluates curcumin's anti-cancer effects at clinically relevant concentrations, revealing unexpected pro-survival effects in some cancer cells.

## Key findings

- At 4 µg/mL, curcumin did not reduce cell viability and increased nuclear Cyclin D1 in some cancer cells.
- Procaspase-3 levels were unchanged at low concentrations, indicating no apoptosis.
- Higher concentrations (20–50 µg/mL) showed some reduction in procaspase-3 in specific cell lines.

## Abstract

Curcumin, a dietary polyphenol derived from turmeric, has been widely studied for its anti-cancer properties, yet its effects at clinically relevant concentrations remain unclear. This study investigates the anti-cancer effects of curcumin at low in vitro concentrations selected based on reported plasma ranges using in vitro lung and CRC models, with a focus on underlying cellular mechanisms.

Curcumin was tested at 4, 10, 20, and 50 µg/mL in two CRC cell lines (Caco-2 and HT29) and two lung cancer cell lines (A549 and H460).

MTS assays showed that at a low concentration of Curcumin 4 µg/mL, cell viability remained above 100% across all cell lines (A549: 102.1%, H460: 101.1%, Caco-2: 103.6%, HT29: 104.9%, n = 3, p > 0.05) and had no significant effect on cell death. Immunofluorescence analysis showed increased nuclear Cyclin D1 levels at 4 µg/mL curcumin in H460 and HT29 cells (p < 0.001), and no change in Caco-2 cells (p = 0.17), and a significant reduction in A549 cells (p < 0.001), suggesting promotion of cell cycle progression in H460 and HT29 cells only. Western blotting analysis showed higher levels of procaspase-3 without evidence of cleavage at 4 µg/mL, indicating the absence of apoptosis. A reduction in procaspase 3 levels were observed at 20 µg/mL (Caco-2, p < 0.05) and 50 µg/mL (H460, p < 0.05; A549, and HT29, p > 0.05).

These findings suggest that at low. plasma level-informed concentrations, curcumin may support cancer cell survival rather than induce cytotoxicity. This study highlights the need for further pre-clinical evaluation of polyphenols at clinically relevant concentrations.

## Linked entities

- **Genes:** ccnd1.S (cyclin D1 S homeolog) [NCBI Gene 379161]
- **Chemicals:** curcumin (PubChem CID 969516)
- **Diseases:** lung cancer (MONDO:0005138), colorectal cancer (MONDO:0005575)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, TUBA1B (tubulin alpha 1b) [NCBI Gene 10376] {aka K-ALPHA-1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, COL11A2 (collagen type XI alpha 2 chain) [NCBI Gene 1302] {aka DFNA13, DFNB53, FBCG2, HKE5, OSMEDA, OSMEDB}, MYB (MYB proto-oncogene, transcription factor) [NCBI Gene 4602] {aka Cmyb, c-myb, c-myb_CDS, efg}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, ACSL4 (acyl-CoA synthetase long chain family member 4) [NCBI Gene 2182] {aka ACS4, FACL4, LACS4, MRX63, MRX68, XLID63}, HRAS (HRas proto-oncogene, GTPase) [NCBI Gene 3265] {aka C-BAS/HAS, C-H-RAS, C-HA-RAS1, CTLO, H-RASIDX, HAMSV}, MAP2K3 (mitogen-activated protein kinase kinase 3) [NCBI Gene 5606] {aka MAPKK3, MEK3, MKK3, PRKMK3, SAPKK-2, SAPKK2}, SMAD2 (SMAD family member 2) [NCBI Gene 4087] {aka CHTD8, JV18, JV18-1, LDS6, MADH2, MADR2}, SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, ANXA5 (annexin A5) [NCBI Gene 308] {aka ANX5, CPB-I, ENX2, HEL-S-7, PP4, RPRGL3}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) [NCBI Gene 6098] {aka MCF3, ROS, c-ros-1}, MAPK13 (mitogen-activated protein kinase 13) [NCBI Gene 5603] {aka MAPK 13, MAPK-13, PRKM13, SAPK4, p38delta}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, ALK (ALK receptor tyrosine kinase) [NCBI Gene 238] {aka ALK1, CD246, NBLST3}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, NRAS (NRAS proto-oncogene, GTPase) [NCBI Gene 4893] {aka ALPS4, CMNS, N-ras, NCMS, NRAS1, NS6}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}
- **Diseases:** inflammatory (MESH:D007249), CRC (MESH:D015179), lung (MESH:D008171), pleural effusion (MESH:D010996), necrosis (MESH:D009336), diarrhea (MESH:D003967), cytotoxicity (MESH:D064420), colorectal adenocarcinoma (MESH:D003110), NSCLC (MESH:D002289), lung cancer (MESH:D008175), death (MESH:D003643), Cancer (MESH:D009369), Iron overload (MESH:D019190), metastasis (MESH:D009362), Large cell lung cancers (MESH:D055752), lung adenocarcinoma (MESH:D000077192), inflammatory bowel disease (MESH:D015212), leaky gut syndrome (MESH:C535298), lesion (MESH:D009059)
- **Chemicals:** lipid (MESH:D008055), NaCl (MESH:D012965), MTT (MESH:C070243), Alexa Fluor  488 (MESH:C000711379), Laemmli buffer (MESH:C088816), amide (MESH:D000577), 5-fluorouracil (MESH:D005472), epigallocatechin gallate (MESH:C045651), EDTA (MESH:D004492), polyphenol (MESH:D059808), crocetin (MESH:C487773), CCK-8 (MESH:D012844), CO2 (MESH:D002245), piperine (MESH:C008922), Tween-20 (MESH:D011136), iron (MESH:D007501), SDS (MESH:D012967), DAPI (MESH:C007293), paraformaldehyde (MESH:C003043), L-glutamine (MESH:D005973), PBS (MESH:D007854), GSH (MESH:D005978), Staurosporine (MESH:D019311), PI (MESH:D010716), Erastin (MESH:C477224), penicillin (MESH:D010406), DMSO (MESH:D004121), Triton X-100 (MESH:D017830), tetrahydrocurcumin (MESH:C096277), D8418 (-), Rhodamine Phalloidin (MESH:C504731), ROS (MESH:D017382), dihydrocurcumin (MESH:C476661), sulfate (MESH:D013431), PUFAs (MESH:D005231), glucuronide (MESH:D020719), Curcumin (MESH:D003474), PVDF (MESH:C024865), streptomycin (MESH:D013307), lipid peroxides (MESH:D008054), TX100 (MESH:C551282)
- **Species:** Homo sapiens (human, species) [taxon 9606], Piper nigrum (species) [taxon 13216], Mus musculus (house mouse, species) [taxon 10090], Crocus (genus) [taxon 58949], Curcuma longa (turmeric, species) [taxon 136217]
- **Cell lines:** HT29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320), A549 lung cancer — Homo sapiens (Human), Lung squamous cell carcinoma, Cancer cell line (CVCL_3008), H460 — Homo sapiens (Human), Lung large cell carcinoma, Cancer cell line (CVCL_0459), L1210/0 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_Y418), HCT116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), Caco-2 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0025), A549:1.7 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_A1ZW)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13007458/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13007458/full.md

## References

69 references — full list in the complete paper: https://tomesphere.com/paper/PMC13007458/full.md

---
Source: https://tomesphere.com/paper/PMC13007458